Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Up Front MattersEditorials
You have accessRestricted Access

Epigenetic Changes Induced by Hypoxia-Inducible Factor: a Long Way Still To Go as a Target for Therapy?

Masaomi Nangaku, Reiko Inagi, Imari Mimura and Tetsuhiro Tanaka
JASN July 2015, 26 (7) 1478-1480; DOI: https://doi.org/10.1681/ASN.2014121161
Masaomi Nangaku
*Division of Nephrology and Endocrinology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reiko Inagi
†Division of Chronic Kidney Disease Pathophysiology, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Imari Mimura
‡Research Center for Advanced Science and Technology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetsuhiro Tanaka
*Division of Nephrology and Endocrinology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • hypoxia
  • chronic kidney disease
  • acute renal failure
  • HIF
  • microRNA
  • AKI

MicroRNA (miR) are small noncoding RNA molecules that regulate gene expression and play important roles during kidney development, homeostasis, and disease. Novel contributions to the field of cell death, cell cycle, and miR regulation in the kidney have come from the Laboratory of Dong, and in the present issue of JASN, a study from this laboratory clarifies a role of miR-687 as a key regulator and therapeutic target in acute ischemic injury to the kidney.1 AKI is associated with high morbidity and mortality and is closely intertwined with CKD, with each disease serving as a risk factor for developing the other and sharing causes and other risk factors in common. Furthermore, ischemia is a major cause of AKI, and hypoxia serves as a final common pathway to end stage kidney failure. Therefore, their choice of a model is appropriate.

The authors used microarrays and profiled miR expression in kidney tissues rendered to ischemia reperfusion. Among the miR, miR-687 showed a highest up-regulation at 12 hours of reperfusion. Their beautiful in situ hybridization study localized miR-687 induction predominantly in the cells of renal cortical tubules.

Then the authors studied the upstream of miR-687 induction and found that miR-687 induction was mediated by a transcriptional factor, hypoxia-inducible factor-1 (HIF-1), that plays an integral role in the body's response to low oxygen concentrations.2,3 The amount of HIF-1 is regulated mainly at the degradation of HIF-1α via hydroxylation of the proline residues and subsequent polyubiquitylation by the von Hippel–Lindau protein that acts as its E3 ligase. This proline hydroxylation is regulated by oxygen-dependent activity prolyl hydroxylases (PHD) that belong to the family of iron- and 2-oxoglutamate-dependent dioxygenase enzyme, and hypoxia inactivates PHD, allowing HIF-1α to escape degradation. Then the α subunit translocates to the nucleus where it forms a heterodimer with a constitutively expressed β-subunit and transactivates 100–200 target genes. The representative HIF target genes include those involved in erythropoiesis (e.g., erythropoietin) and those involved in angiogenesis (e.g., vascular endothelial growth factor) to increase oxygen delivery to tissues. The authors used HIF-1α-null mouse embryonic fibroblasts and proximal tubule-specific HIF-1α knockout mice, confirming HIF-1-dependent miR-687 induction. This demonstration of specificity is important because HIF has two active isoforms, HIF-1 and HIF-2. HIF-1α and HIF-2α have 48% amino acid sequence identity, but they are often nonredundant and have distinct target genes. This isoform specificity can explain tubular specific localization of miR-687 because HIF-1α is expressed in tubular cells and HIF-2α is expressed in endothelial cells and interstitial cells in the kidney.4

To investigate the downstream pathway of miR-687, the authors predicted targets of miR-687 using several databases and confirmed phosphatase and tensin homolog (PTEN), a modulator of cell cycle and cell death, as the downstream gene target. As previously described, HIF-1 is a master regulator of adaptive responses against hypoxia, and their functional studies using cultured tubular cells suggested that miR-687-mediated downregulation of PTEN facilitated cell cycle progression for tubular cell proliferation and kidney repair during hypoxia. Previous studies of experimental animals demonstrated protective effects of pharmacologic HIF activation against ischemia reperfusion injury of the kidney, and miR-687-mediated downregulation of PTEN may be one of the mechanisms of renoprotection by HIF activation.5,6

However, the authors’ functional studies of mice showed paradoxical results. The authors used locked-nucleic-acid oligonucleotides to neutralize the effects of miR-687 in vivo. Mice treated with anti-miR-687 developed significantly less kidney injury as evidenced by the examination of physiologic parameters, histology, and renal apoptosis. Therefore, blockade of miR-687 and preservation of PTEN expression resulted in protection against kidney injury in vivo. Although HIF-1 is the most potent defensive mechanism against hypoxia, it regulates a number of pathways. It is possible that miR-687 induced by HIF-1 may provoke proapoptotic responses in a PTEN-independent manner. The presence of other types of cells beside tubular cells may explain the discrepancy from the in vitro experimental system composed of exclusively tubular cells. In addition, various stresses, such as oxidative stress and endoplasmic reticulum stress interact together, complicating the disease manifestations after ischemia reperfusion injury in animals. Currently, a number of PHD inhibitors to active HIF and upregulate erythropoietin, a representative target of HIF, are currently undergoing clinical trials of anemia in CKD. This study suggests context-dependent effects of miR-687 induced by HIF-1. Context-dependent outcomes of HIF activation therapy were also reported in the remnant kidney model, a representative model of chronic kidney failure.7 These findings emphasize the importance of understanding the complicated downstream pathways for estimation of efficacy and safety of HIF activation therapy.

Demonstration of epigenetic changes regulated by HIF-1-dependent miR expression is pathophysiologically important. Epigenetic regulation includes changes in DNA methylation, histone modifications, chromosomal conformational changes, and alteration in miR expression. Although the study clearly demonstrated a critical role of miR induced by HIF-1, recent studies also showed other epigenetic regulation mechanisms by HIF-1, such as histone modification and chromosomal conformational change.8 HIF-1 target genes include histone lysine demethylases (lysine (K)-specific demethylases or Jumonji C lysine demethylases). Lysine (K)-specific demethylases belong to the family of iron- and 2-oxoglutamate-dependent dioxygenase enzyme like PHD, suggesting an intricate link between oxygen tensions and histone modifications. Oxygen-dependent epigenetic regulation is a focus of intensive researches today.

There are some unanswered questions. A previous study showed that loss of PTEN increases the transcriptional activity of HIF-1 through the inactivation of Forkhead transcription factors,9 and it remains to be determined whether the miR-687-mediated downregulation of PTEN by HIF-1 makes up a positive feedback loop. Our previous study showed a protective role of miR-205 against hypoxia reoxygenation via the suppression of PHD1.10 As previously described, PHD controls the amount of HIF-1, suggesting a role of miR-205 in regulation of HIF-1. Furthermore, HIF-1 also regulates various miR, and miR-21 is one of the most intensively studied miR regulated by HIF-1.11 The complex network of HIF-1 and miR is a critical subject for future studies.

PTEN is also known to be involved in a network of interactions with p53, which transcriptionally activates genes involved in cell cycle control and apoptosis. PTEN regulates p53 protein levels and transcriptional activity through both phosphatase dependent and independent mechanisms. A crucial role of p53 in tubules damaged by ischemia reperfusion has been reported by the authors’ group and others,12–14 and a role of p53 in the HIF-1/miR-687/PTEN signaling pathway is an important issue to be pursued.

Finally, hypoxia is a condition of energy depletion caused by disturbance of aerobic respiration of mitochondria. HIF-1 plays a critical role in energy metabolism, reprogramming cellular metabolism toward enhanced glycolysis and reduced oxidative phosphorylation (i.e., Warburg effect). Recent studies clarified the functional role of HIF-1-induced large intergenic ncRNA-p21 (lincRNA-p21) in this metabolic reprogramming. LincRNA-p21 is rapidly induced by HIF-1α, and lincRNA-p21 then disrupts the HIF-1α von Hippel–Lindau interaction, stabilizes HIF-1α, and increases expression of HIF-1α-responsive genes (e.g., glycolytic enzymes Glut1 and LDHA), thereafter promoting glycolysis and reprogramming cellular metabolism.15 Regulation of energy metabolism by the HIF-1/miR-687/PTEN signaling pathway should be investigated in the future.

This study is well-conducted with sophisticated techniques, validating the observations using independent methodologies from various aspects. Thomas Edison gave us the aphorism “Everything comes to him who hustles while he waits” that emphasizes the importance of the energetic and ongoing pursuit of a given goal. The work of Bhatt and colleagues is a wonderful example of how the vigorous and unremitting exploration of mechanisms underlying acute ischemic injury can lead to rewarding insights, including those, as shown in this study, regarding miR-687 and HIF delineation of the novel HIF-1/miR-687/PTEN signaling pathway providing new insights into the understanding of the pathogenesis of AKI to develop novel therapeutic approaches.

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related article, “MicroRNA-687 Induced by Hypoxia-Inducible Factor-1 Targets Phosphatase and Tensin Homolog in Renal Ischemia-Reperfusion Injury,” on pages 1588–1596.

  • Copyright © 2015 by the American Society of Nephrology

References

  1. ↵
    1. Bhatt K,
    2. Wei Q,
    3. Pabla N,
    4. Dong G,
    5. Mi Q-S,
    6. Mei C,
    7. Dong Z
    : MicroRNA-687 induced by HIF-1 targets PTEN in renal ischemia-reperfusion injury. J Am Soc Nephrol 26: 1588–1596, 2015
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Tanaka T,
    2. Nangaku M
    : Angiogenesis and hypoxia in the kidney. Nat Rev Nephrol 9: 211–222, 2013
    OpenUrlCrossRefPubMed
  3. ↵
    1. Nangaku M
    : Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J Am Soc Nephrol 17: 17–25, 2006
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Rosenberger C,
    2. Mandriota S,
    3. Jürgensen JS,
    4. Wiesener MS,
    5. Hörstrup JH,
    6. Frei U,
    7. Ratcliffe PJ,
    8. Maxwell PH,
    9. Bachmann S,
    10. Eckardt KU
    : Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13: 1721–1732, 2002
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Schley G,
    2. Klanke B,
    3. Schödel J,
    4. Kröning S,
    5. Türkoglu G,
    6. Beyer A,
    7. Hagos Y,
    8. Amann K,
    9. Burckhardt BC,
    10. Burzlaff N,
    11. Eckardt KU,
    12. Willam C
    : Selective stabilization of HIF-1α in renal tubular cells by 2-oxoglutarate analogues. Am J Pathol 181: 1595–1606, 2012
    OpenUrlCrossRefPubMed
  6. ↵
    1. Matsumoto M,
    2. Makino Y,
    3. Tanaka T,
    4. Tanaka H,
    5. Ishizaka N,
    6. Noiri E,
    7. Fujita T,
    8. Nangaku M
    : Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol 14: 1825–1832, 2003
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Yu X,
    2. Fang Y,
    3. Liu H,
    4. Zhu J,
    5. Zou J,
    6. Xu X,
    7. Jiang S,
    8. Ding X
    : The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration. Nephrol Dial Transplant 27: 3110–3119, 2012
    OpenUrlCrossRefPubMed
  8. ↵
    1. Mimura I,
    2. Tanaka T,
    3. Nangaku M
    : Novel therapeutic strategy with hypoxia-inducible factors via reversible epigenetic regulation mechanisms in progressive tubulointerstitial fibrosis. Semin Nephrol 33: 375–382, 2013
    OpenUrlCrossRefPubMed
  9. ↵
    1. Emerling BM,
    2. Weinberg F,
    3. Liu JL,
    4. Mak TW,
    5. Chandel NS
    : PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci U S A 105: 2622–2627, 2008
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Muratsu-Ikeda S,
    2. Nangaku M,
    3. Ikeda Y,
    4. Tanaka T,
    5. Wada T,
    6. Inagi R
    : Downregulation of miR-205 modulates cell susceptibility to oxidative and endoplasmic reticulum stresses in renal tubular cells. PLoS One 7: e41462, 2012
    OpenUrlCrossRefPubMed
  11. ↵
    1. Xu X,
    2. Kriegel AJ,
    3. Liu Y,
    4. Usa K,
    5. Mladinov D,
    6. Liu H,
    7. Fang Y,
    8. Ding X,
    9. Liang M
    : Delayed ischemic preconditioning contributes to renal protection by upregulation of miR-21. Kidney Int 82: 1167–1175, 2012
    OpenUrlCrossRefPubMed
  12. ↵
    1. Zhang D,
    2. Liu Y,
    3. Wei Q,
    4. Huo Y,
    5. Liu K,
    6. Liu F,
    7. Dong Z
    : Tubular p53 regulates multiple genes to mediate AKI. J Am Soc Nephrol 25: 2278–2289, 2014
    OpenUrlAbstract/FREE Full Text
    1. Peng J,
    2. Li X,
    3. Zhang D,
    4. Chen JK,
    5. Su Y,
    6. Smith SB,
    7. Dong Z
    : Hyperglycemia, p53, and mitochondrial pathway of apoptosis are involved in the susceptibility of diabetic models to ischemic acute kidney injury [published online ahead of print June 25, 2014]. Kidney Int
  13. ↵
    1. Ying Y,
    2. Kim J,
    3. Westphal SN,
    4. Long KE,
    5. Padanilam BJ
    : Targeted deletion of p53 in the proximal tubule prevents ischemic renal injury. J Am Soc Nephrol 25: 2707–2716, 2014
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Yang F,
    2. Zhang H,
    3. Mei Y,
    4. Wu M
    : Reciprocal regulation of HIF-1α and lincRNA-p21 modulates the Warburg effect. Mol Cell 53: 88–100, 2014
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 26 (7)
Journal of the American Society of Nephrology
Vol. 26, Issue 7
July 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Epigenetic Changes Induced by Hypoxia-Inducible Factor: a Long Way Still To Go as a Target for Therapy?
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Epigenetic Changes Induced by Hypoxia-Inducible Factor: a Long Way Still To Go as a Target for Therapy?
Masaomi Nangaku, Reiko Inagi, Imari Mimura, Tetsuhiro Tanaka
JASN Jul 2015, 26 (7) 1478-1480; DOI: 10.1681/ASN.2014121161

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Epigenetic Changes Induced by Hypoxia-Inducible Factor: a Long Way Still To Go as a Target for Therapy?
Masaomi Nangaku, Reiko Inagi, Imari Mimura, Tetsuhiro Tanaka
JASN Jul 2015, 26 (7) 1478-1480; DOI: 10.1681/ASN.2014121161
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

Up Front Matters

  • Predicting Future Outcomes from Kidney Biopsies with MCD/FSGS Lesions: Opportunities and Limitations
  • Kidney Health Disparities: The Goal is Elimination
  • Autoimmune Renal Calcium and Magnesium Wasting
Show more Up Front Matters

Editorials

  • A Novel Pathological Mechanism of Tertiary Lymphoid Structure Formation in the Renal Pelvis
  • Disarming the Old Foe. Restoring T-Cell Immune Function with mTor-Inhibitors to Tackle Cytomegalovirus Infection
  • Genome-wide Admixture Mapping of eGFR and CKD Identify European and African Ancestry-of-Origin Loci in US Hispanics/Latinos
Show more Editorials

Cited By...

  • Current epigenetic aspects the clinical kidney researcher should embrace
  • Google Scholar

Similar Articles

Related Articles

  • MicroRNA-687 Induced by Hypoxia-Inducible Factor-1 Targets Phosphatase and Tensin Homolog in Renal Ischemia-Reperfusion Injury
  • PubMed
  • Google Scholar

Keywords

  • hypoxia
  • chronic kidney disease
  • acute renal failure
  • HIF
  • microRNA
  • AKI

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire